Indication and Limitation of Use

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13)… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test… read more

Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use: as first-line therapy in combination with FOLFOX, as monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

×
×

You are now leaving Vectibix.com

Please know that the sponsors of this site are not responsible for content on the site you are about to enter.

Cancel
Continue
Approved In
First Line
Since
20141

IN PATIENTS WITH WT KRAS* (NOT RAS MUTANT) mCRC

Spot the difference

Choose Vectibix®

MEET A HYPOTHETICAL PATIENT WITH FIRST-LINE mCRC MEET A HYPOTHETICAL PATIENT WITH THIRD-LINE mCRC

*Exon 2 in codons 12 or 13.2

These case studies are hypothetical examples and do not represent actual patients.

mCRC = metastatic colorectal cancer; WT = wild type.


<
>

Site Map

×